CDCA3 mediates p21-dependent proliferation by regulating E2F1 expression in colorectal cancer

Area of Science:

• Oncology
• Molecular Biology
• Cell Biology

Background:

• Dysregulated cell cycle progression is fundamental to cancer development.
• Cell division cycle-associated 3 (CDCA3) is a key regulator of mitotic entry and part of ubiquitin ligase complexes.
• The specific role of CDCA3 in colorectal cancer (CRC) remains largely unexplored.

Purpose of the Study:

• To investigate the biological and clinical significance of CDCA3 in the growth and progression of colorectal cancer.
• To elucidate the mechanisms by which CDCA3 influences CRC cell proliferation and cell cycle regulation.

Main Methods:

• Analysis of CDCA3 expression in relation to tumor progression and patient survival.
• In vitro and in vivo experiments involving CDCA3 overexpression (LoVo cells) and knockdown (SW480 cells).
• Cell cycle analysis (G1/S transition) and assessment of key regulatory proteins (p21, E2F1).

Main Results:

• CDCA3 expression levels were significantly associated with colorectal cancer progression and poorer patient survival.
• CDCA3 overexpression enhanced proliferation in LoVo CRC cells, while knockdown reduced proliferation in SW480 CRC cells (in vitro and in vivo).
• CDCA3 modulated G1/S phase transition by regulating p21 accumulation, partly through the E2F1 transcription factor.

Conclusions:

• Overexpression of CDCA3 contributes to the malignant potential of colorectal cancer.
• CDCA3 plays a significant role in regulating cell cycle progression in CRC.
• CDCA3 represents a potential prognostic biomarker and therapeutic target for colorectal cancer.